Evaluation of the safety and effectiveness of CIMAher(R) (Nimotuzumab) in the treatment of patients with locally advanced adenocarcinoma of pancreas and unresectable or metastatic. Phase IV

Trial Profile

Evaluation of the safety and effectiveness of CIMAher(R) (Nimotuzumab) in the treatment of patients with locally advanced adenocarcinoma of pancreas and unresectable or metastatic. Phase IV

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Nimotuzumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top